Morgan Stanley Maintains Equal-Weight on NeoGenomics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on NeoGenomics (NASDAQ:NEO) and lowered the price target from $19 to $18.
August 09, 2023 | 1:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on NeoGenomics and lowered the price target from $19 to $18.
The lowering of the price target by Morgan Stanley could potentially lead to a decrease in the stock price of NeoGenomics in the short term. The Equal-Weight rating indicates that the stock is expected to perform in line with the market or other stocks in its sector.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100